Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Crinetics Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Crinetics Pharmaceuticals's regulatory disclosures and financial reporting.
Crinetics Pharmaceuticals, Inc. filed its Form 10-K reporting operations for the fiscal year ended December 31, 2025. The company is a commercial-stage endocrine-focused biopharma with an FDA-approved product, PALSONIFY (paltusotine), and a diversified pipeline including atumelnant and the NDC candidate CRN09682.
The filing highlights FDA approval of PALSONIFY on September 25, 2025 and U.S. commercial availability in October 2025, ongoing global regulatory activity including a CHMP positive opinion in February 2026, multiple active Phase 1–3 programs, third-party manufacturing and distribution arrangements, and intellectual property estate with patent expirations estimated through the mid-2040s.
Crinetics Pharmaceuticals is holding its 2026 annual shareholder meeting on June 18, 2026 via live webcast. Shareholders of record as of April 20, 2026, when 105,439,535 common shares were outstanding, can vote.
Three Class II directors are up for election, PricewaterhouseCoopers LLP is proposed as the new independent auditor for 2026, and shareholders will cast an advisory “say‑on‑pay” vote on named executive officer compensation. The eight‑member board is majority independent, led by an independent chair, with specialized audit, compensation, nominating, R&D, and commercialization committees. Non‑employee directors receive cash retainers and equity awards under a structured program, and several institutional investors each hold over 7% of the stock.
CRNX filing reports proposed and recent sales of Common Stock by an affiliated holder. The filing lists an exercise of stock options for 20,900 shares on 04/14/2026 (cash exercise) and multiple 10b5-1 sales executed by Jeff Knight: 9,911 shares on 03/16/2026, 85,163 shares on 04/08/2026, and 4,434 shares on 04/13/2026, with cash proceeds shown per trade.
Morgan Stanley Smith Barney LLC reported a Form 144 notice for sale of 4,434 shares of Common Stock of CRNX tied to exercise of stock options on 04/13/2026. The filing also lists prior 10b5-1 sales by Jeff Knight: 85,163 shares on 04/08/2026 and 9,911 shares on 03/16/2026, with proceeds shown in the filing.
Crinetics Pharmaceuticals Chief Dev. & Operating Officer Jeff E. Knight reported an exercise-and-sale transaction in company stock. On April 8, 2026, he exercised stock options to acquire a total of 78,434 shares of Common Stock at exercise prices of $23.98, $20.02, and $19.64 per share.
On the same date, Knight sold 85,163 shares of Common Stock in open market transactions at a volume weighted average price of $40.10 per share, with individual sale prices ranging from $40.00 to $40.34. The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 105,289 shares of Crinetics common stock.
Crinetics Pharmaceuticals, Inc. reports that Jeff Knight’s previously disclosed resignation as Chief Development and Operating Officer became effective on April 10, 2026. On that date, the company and Mr. Knight entered into an Independent Consultant Agreement covering operational and clinical development services.
The consulting term runs from April 10, 2026 to April 10, 2027, with an option to renew for six months if both sides agree in writing. Mr. Knight will be paid $400 per hour, up to 20 hours per month, plus reimbursement of reasonable pre-approved expenses. His unvested restricted stock units and stock options are forfeited on the resignation date, while vested options remain exercisable for three months after the consulting period ends or earlier termination for cause. He also provides a general release of claims, and the company extends certain indemnification rights during the consulting term.
CRNX files a Form 144 disclosing proposed resale transactions of its Common Stock. The notice lists a reported sale of $370,411.47 for 9,911 shares on 03/16/2026. The filing also itemizes securities related to exercise of stock options (78,434 shares, 04/08/2026), an Employee Stock Purchase Plan entry (438 shares, 05/20/2025), and Restricted Stock Units (6,291 shares, 03/15/2024).
The Form 144 is a notice of proposed sale by an affiliate and describes the method of sale as cash transactions. It reports the broker/dealer and issuer entries tied to each lot; the filing does not state additional proceeds disposition or timing beyond the listed dates.
Crinetics Pharmaceuticals receives an amended Schedule 13G from The Vanguard Group reporting beneficial ownership of 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under which certain Vanguard subsidiaries report holdings separately.
The filing is signed March 26, 2026 by Ashley Grim, Head of Global Fund Administration, and lists Vanguard's Malvern, Pennsylvania address and Crinetics' principal executive office in San Diego.
Crinetics Pharmaceuticals announced that Jeff Knight has decided to resign as Chief Development and Operating Officer, effective on or about April 10, 2026. The company states that he is leaving to pursue another opportunity and that his resignation is not due to any disagreement over operations, policies, or practices.
Crinetics plans to reassign all of Mr. Knight’s managerial responsibilities and direct reports to other members of its executive leadership team, signaling a redistribution of his duties rather than the creation of a new replacement role at this time.
Crinetics Pharmaceuticals Chief Operating Officer Jeff E. Knight sold 9,911 shares of common stock in open-market transactions. The sales on March 16, 2026 were executed at volume-weighted average prices of $37.11 and $37.77 per share.
According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of previously granted restricted stock units and were carried out by a broker under a Rule 10b5-1 trading plan. After the transactions, Knight directly holds 112,018 shares of Crinetics common stock.